ClinicalTrials.gg
RecruitingNCT07943390Updated Nov 17, 2026

A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza

A Phase 3 interventional study of BRC-201 and Placebo in Influenza, sponsored by Boryung Biopharma Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 12 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Boryung Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
12 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Influenza, Human with a site in Korea, Republic of — 9 open to participants now, 10 under way, 4 of them phase 3. Influenza, Human · Korea, Republic of.

Planned enrollment
22nd of 55
348 · median 274
Started
2026
with 6 others
Phase 3
28 of 60
3 open now
Registered
60th of 60
by date

Among the 60 studies in Influenza, Human with a site in Korea, Republic of, this one is the 22nd largest by planned enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2026, is one of 28 in phase 3, and was the 60th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

9 of the 60 studies in Influenza, Human with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 12 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Influenza, Human with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, double-blind clinical study designed to evaluate the efficacy and safety of BRC-201 in adult and adolescent patients with acute uncomplicated influenza virus infection.

The study aims to assess the efficacy of BRC-201 in treating influenza symptoms and to evaluate its safety in patients with influenza.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Influenza A
  • Influenza B
  • Acute Uncomplicated Influenza
  • BRC-201
  • TG-1000
  • Pixavir Marboxil
04

Who can participate

Ages eligible
12 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 12 to less than 65 years who provide written or assent, as applicable.
  2. Laboratory-confirmed influenza A and/or B infection by RIDT or PCR, with an axillary temperature ≥38.0°C and at least one systemic and one respiratory symptom of moderate or greater severity (score ≥2).
  3. Onset of influenza-related symptoms within 48 hours before randomization.
  4. Willing and able to comply with the protocol-specified requirements.
  5. Able to comply with study procedures, scheduled visits, and symptom diary completion.

Exclusion criteria

Exclusion Criteria:

  1. Severe or critical influenza infection requiring hospitalization or intensive care.
  2. Significant uncontrolled underlying diseases or conditions associated with an increased risk of severe influenza, including immunodeficiency and hepatic, renal, cardiovascular, or respiratory diseases.
  3. Suspected or confirmed lower respiratory tract disease on chest X-ray, recent acute respiratory infection, or concomitant infection requiring systemic antimicrobial treatment.
  4. Clinically significant infection-related findings, including leukocyte count >10.0 × 10⁹/L, purulent sputum, or purulent tonsillitis.
  5. History of dysphagia, gastrointestinal conditions affecting drug absorption, or to the product, acetaminophen, or NSAIDs.
  6. >30.0 kg/m², body weight \<40.0 kg, or positive COVID-19 test at screening.
  7. Use of anti-influenza medication within 7 days, or another investigational drug or device treatment within 30 days before randomization.
  8. Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
348 participants (estimated)

Study arms

  • Experimental
    BRC-201

    Participants will receive a single oral dose of BRC-201 (40 mg for participants weighing less than 80 kg or 80 mg for those weighing 80 kg or more).

    Drug: BRC-201

  • Placebo comparator
    Placebo

    Participants will receive a single oral dose of placebo matching BRC-201 (2 capsules for participants weighing less than 80 kg or 4 capsules for those weighing 80 kg or more).

    Drug: Placebo

Interventions

  • BRC-201 (pixavir marboxil) 20 mg capsules administered orally as a single dose of 40 mg (2 capsules) for participants weighing less than 80 kg or 80 mg (4 capsules) for participants weighing 80 kg or more.

    Also known as: TG-1000, Pixavir Marboxil

  • DrugPlacebo

    Placebo capsules matching BRC-201, administered orally as a single dose of 2 capsules for participants weighing less than 80 kg or 4 capsules for participants weighing 80 kg or more.

06

What researchers measure

Primary outcomes

  1. Time to Alleviation of Influenza-related Symptoms (TTAS)

    Time (hours) from the initiation of investigational medicinal product administration until all seven influenza-related symptoms (cough, sore throat, nasal congestion, headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain) are alleviated. Symptom alleviation is defined as a severity score of 0 (none) or 1 (mild) for all seven symptoms, maintained for at least 21.5 hours.

    Time frame: From Day 1 (post-dose) through Day 14

Secondary outcomes

  1. Percentage of Participants With Alleviation of Influenza-related Symptoms at Each Time Point

    The percentage of participants whose severity scores for all seven influenza-related symptoms (cough, sore throat, nasal congestion, headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain) are 0 (none) or 1 (mild), with symptom alleviation maintained for at least 21.5 hours, at each assessment time point.

    Time frame: From Day 1 (post-dose) through Day 14

  2. Change From Baseline in Composite Influenza Symptom Score at Each Time Point

    Change from baseline in the composite score of seven influenza-related symptoms (cough, sore throat, nasal congestion, headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain). Each symptom is assessed using a 4-point severity scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). The composite score ranges from 0 to 21, with higher scores indicating greater symptom severity. The change is calculated as the score at each post-baseline assessment minus the baseline score.

    Time frame: Baseline (Day 1, pre-dose) through Day 14

  3. Time to Alleviation of Four Systemic Influenza Symptoms

    Time (hours) from the initiation of investigational medicinal product administration until all four systemic influenza symptoms (headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain) are alleviated. Symptom alleviation is defined as a severity score of 0 (none) or 1 (mild) for all four systemic symptoms.

    Time frame: From Day 1 (post-dose) through Day 14

  4. Time to Alleviation of Three Respiratory Influenza Symptoms

    Time (hours) from the initiation of investigational medicinal product administration until all three respiratory influenza symptoms (cough, sore throat, and nasal congestion) are alleviated. Symptom alleviation is defined as a severity score of 0 (none) or 1 (mild) for all three respiratory symptoms.

    Time frame: From Day 1 (post-dose) through Day 14

  5. Time to Alleviation of Each Individual Influenza-related Symptom

    Time (hours) from the initiation of investigational medicinal product administration until alleviation of each of the seven influenza-related symptoms (cough, sore throat, nasal congestion, headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain). Alleviation of an individual symptom is defined as a severity score of 0 (none) or 1 (mild), maintained for at least 21.5 hours. Each symptom will be evaluated separately. Participants with a baseline severity score of 0 or 1 for a specific symptom will be excluded from the analysis of that symptom.

    Time frame: From Day 1 (post-dose) through Day 14

  6. Percentage of Participants With Normalized Body Temperature at Each Time Point

    The percentage of participants whose body temperature returned to normal at each assessment time point after investigational medicinal product administration. Normalization of body temperature is defined as an axillary temperature below 37.0°C.

    Time frame: From Day 1 (post-dose) through Day 14

  7. Time to Resolution of Fever

    Time (hours) from the initiation of investigational medicinal product administration until resolution of fever. Fever resolution is defined as body temperature below 37.0°C, maintained for at least 12 hours.

    Time frame: From Day 1 (post-dose) through Day 14

  8. Body Temperature at Each Time Point

    Axillary body temperature (°C) measured by participants using an electronic thermometer at each assessment time point after investigational medicinal product administration. Body temperature will be summarized by treatment group at each time point.

    Time frame: From Day 1 (post-dose) through Day 14

  9. Time to Recovery to Pre-influenza Health Status

    Time (hours) from the initiation of investigational medicinal product administration until recovery to pre-influenza health status. Recovery is defined as a participant-reported health status score greater than or equal to the pre-influenza health status score recorded before dosing on Day 1. Health status is assessed using an 11-point scale ranging from 0 (worst health status) to 10 (normal health status considering the participant's age and condition).

    Time frame: From Day 1 (post-dose) through Day 14

  10. Change From Baseline in EuroQol Visual Analog Scale (EQ VAS) Score at Each Time Point

    Change from baseline in the EuroQol Visual Analog Scale (EQ VAS) score at each post-baseline assessment time point. Participants rate their overall health status on a scale ranging from 0 (the worst health they can imagine) to 100 (the best health they can imagine). Higher scores indicate better self-reported health status. Change from baseline is calculated as the post-baseline EQ VAS score minus the baseline score.

    Time frame: Baseline (Day 1, pre-dose) through Day 14

  11. Incidence of Influenza-related Complications

    The percentage of participants experiencing influenza-related complications, including hospitalization, death, sinusitis, bronchitis, otitis media, and radiographically confirmed pneumonia. Complications are assessed by the investigator at each scheduled study visit. The number and percentage of participants experiencing complications and the number of occurrences will be summarized by treatment group.

    Time frame: From Day 1 (post-dose) through Day 15 (±2 days)

  12. Percentage of Participants Receiving Rescue Medication and Frequency of Administration

    The percentage of participants who receive rescue medication (acetaminophen) at least once after investigational medicinal product administration and the number of rescue medication administrations. Rescue medication use, including the date, time, and dose of each administration, is recorded in the participant diary and summarized by treatment group.

    Time frame: From Day 1 (post-dose) through Day 14

  13. Percentage of Participants With Positive Influenza Virus Titer by Viral Culture at Each Time Point

    The percentage of participants with a positive influenza virus titer by viral culture at each post-dose assessment time point. Positive results are defined as detectable viral titers or values at or above the lower limit of quantification (LLOQ). The percentage will be summarized by treatment group. The analysis includes participants with positive viral RNA results or values at or above the LLOQ by RT-PCR at screening.

    Time frame: From Day 2 through Day 15 (±2 days)

  14. Percentage of Participants With Positive Influenza Viral RNA by RT-PCR at Each Time Point

    The percentage of participants with positive influenza viral RNA results by reverse transcription polymerase chain reaction (RT-PCR) at each post-dose assessment time point. Positive results are defined as detectable viral RNA or viral RNA levels at or above the lower limit of quantification (LLOQ). Results will be summarized by treatment group. The analysis includes only participants with positive viral RNA results or values at or above the LLOQ by RT-PCR at screening.

    Time frame: From Day 2 through Day 15 (±2 days)

  15. Change From Baseline in Influenza Virus Titer at Each Time Point

    Change from baseline in influenza virus titer measured by viral culture at each post-dose assessment time point. Viral titers are expressed as log10 TCID50/mL (50% tissue culture infectious dose per milliliter). Change from baseline is calculated as the post-baseline viral titer minus the baseline viral titer. Negative changes indicate a reduction in infectious viral titer.

    Time frame: Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)

  16. Change From Baseline in Influenza Viral RNA Load at Each Time Point

    Change from baseline in influenza viral RNA load measured by reverse transcription polymerase chain reaction (RT-PCR) at each post-dose assessment time point. Viral RNA load is expressed as log10 viral copies/mL. Change from baseline is calculated as the post-baseline viral RNA load minus the baseline viral RNA load. Negative changes indicate a reduction in viral RNA load.

    Time frame: Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)

  17. Time to Cessation of Influenza Virus Detection

    Time (hours) from the initiation of investigational medicinal product administration to the first assessment at which influenza viral RNA is negative or below the lower limit of quantification (LLOQ), as determined by reverse transcription polymerase chain reaction (RT-PCR) testing of nasopharyngeal swab specimens.

    Time frame: From Day 1 (post-dose) through Day 15 (±2 days)

Other outcomes

  1. PA Gene Polymorphisms and Treatment-emergent Amino Acid Substitutions

    Assessment of polymerase acidic (PA) gene polymorphisms and treatment-emergent amino acid substitutions in evaluable influenza viruses using PA gene sequencing of nasopharyngeal swab specimens.

    Time frame: Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)

  2. Drug Susceptibility of Evaluable Influenza Viruses

    Assessment of antiviral drug susceptibility in evaluable influenza viruses isolated from nasopharyngeal swab specimens collected during the study. Drug susceptibility testing will be performed to evaluate changes in antiviral susceptibility in evaluable viruses.

    Time frame: Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)

  3. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    The percentage of participants experiencing at least one treatment-emergent adverse event (TEAE). A TEAE is defined as an adverse event that occurs after administration of the investigational medicinal product or a pre-existing condition that worsens after administration. TEAEs will be summarized by treatment group according to severity, seriousness, causality, and MedDRA System Organ Class and Preferred Term.

    Time frame: From Day 1 (post-dose) through Day 15 (±2 days)

  4. Percentage of Participants With Serious Adverse Events (SAEs)

    The percentage of participants experiencing at least one serious adverse event (SAE) during the clinical trial. Serious adverse events will be collected regardless of their causal relationship to the investigational medicinal product. The number and percentage of participants with SAEs and the number of events will be summarized by treatment group.

    Time frame: From informed consent through Day 15 (±2 days)

  5. Percentage of Participants With Clinically Significant Laboratory Abnormalities

    The percentage of participants with at least one clinically significant abnormality in clinical laboratory tests, including hematology, blood chemistry, coagulation, and urinalysis. Clinically significant abnormalities are defined as changes from normal or abnormal not clinically significant (NCS) at baseline to abnormal clinically significant (CS) after administration of the investigational medicinal product, as assessed by the investigator.

    Time frame: Baseline (pre-dose) through Day 15 (±2 days)

  6. Change From Baseline in Systolic Blood Pressure

    Change from baseline in systolic blood pressure (mmHg) at scheduled post-dose study visits. Baseline is defined as the most recent measurement before administration of the investigational medicinal product. Change from baseline is calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline (pre-dose) through Day 15 (±2 days)

  7. Change From Baseline in Diastolic Blood Pressure

    Change from baseline in diastolic blood pressure (mmHg) at scheduled post-dose study visits. Baseline is defined as the most recent measurement before administration of the investigational medicinal product. Change from baseline is calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline (pre-dose) through Day 15 (±2 days)

  8. Change From Baseline in Pulse Rate

    Change from baseline in pulse rate (beats/min) at scheduled post-dose study visits. Baseline is defined as the most recent measurement before administration of the investigational medicinal product. Change from baseline is calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline (pre-dose) through Day 15 (±2 days)

  9. Change From Baseline in Respiratory Rate

    Change from baseline in respiratory rate (breaths/min) at scheduled post-dose study visits. Baseline is defined as the most recent measurement before administration of the investigational medicinal product. Change from baseline is calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline (pre-dose) through Day 15 (±2 days)

  10. Percentage of Participants With Clinically Significant 12-Lead ECG Abnormalities

    The percentage of participants with at least one clinically significant abnormality in 12-lead electrocardiogram (ECG) findings after administration of the investigational medicinal product. Clinically significant abnormalities are defined as changes from normal or abnormal not clinically significant (NCS) at baseline to abnormal clinically significant (CS) after administration, as assessed by the investigator.

    Time frame: Baseline (pre-dose) through Day 15 (±2 days)

  11. Percentage of Participants With Clinically Significant Physical Examination Abnormalities

    The percentage of participants with at least one clinically significant abnormality in physical examination findings after administration of the investigational medicinal product. Clinically significant abnormalities are defined as changes from normal or abnormal not clinically significant (NCS) at baseline to abnormal clinically significant (CS) after administration, as assessed by the investigator. Physical examinations include assessments of the mucocutaneous system, lymph nodes, head and neck, chest, abdomen, spine and extremities, and nervous system.

    Time frame: Baseline (pre-dose) through Day 15 (±2 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in publications may be made available to qualified researchers upon reasonable request. Requests will be reviewed by Boryung Biopharma Co., Ltd., considering the scientific merit of the proposed research, participant confidentiality, and applicable regulatory requirements. Approved requests will be subject to a data-sharing agreement.

Access criteria: Qualified researchers may request access to de-identified IPD for scientifically valid research purposes. Requests will be reviewed by the Sponsor on a case-by-case basis. Data access will be granted following approval of the request and execution of an appropriate data-sharing agreement, subject to applicable privacy and regulatory requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 5 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943390
Lead sponsor
Boryung Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Jaehyun Hwang
Contact
jhhwang@boryungbio.co.kr
+82 02-6072-2608

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TG-1000

Start the discussion